Abstract: Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper provides a detailed analysis of the current status and research progress of China's innovative drug market from five perspectives: market size and growth, policy support, technological advancement, overseas market expansion, and capital market support.
Market Size and Growth: Booming Rise of the Innovative Drug Market
The rapid advancement of biopharmaceutical technologies has provided robust support for innovative drug R&D. For instance, the application of cutting-edge technologies such as gene editing, cell therapy, and targeted therapy has yielded remarkable results in treating cancers, rare diseases, and other conditions for innovative drugs. Notably, 91 new drugs were added to the catalog of medicines covered by national medical insurance system in 2024, with 38 of these being "world-first" innovative drugs - a record high in both proportion and absolute numbers.
Over the past decade, China's innovative drug market size has grown at a remarkable pace. In 2019, China's innovative drug market was valued at USD 132.5 billion. By 2023, the market size had surpassed RMB 700 billion. By 2024, it had further expanded to over RMB 1.13 trillion. According to the forecast of Forward Industry Research Institute, the innovative drug market size in China is expected to reach nearly RMB 2.3 trillion by 2030. Among them, the factors driving the continuous growth of China's innovative drug market size are as follows:
Policy support
In 2015, reforms in drug review processes were initiated, reducing clinical trial approval times from three years to 60 days. Priority review channels have accelerated the launch of innovative drugs made in China such as PD-1. Additionally, through annual medical insurance negotiations, the hospital admission cycle for innovative drugs has been shortened from five years to just 1.5 years, accelerating their commercialization and market adoption. Meanwhile, the dynamic adjustment of the medical insurance catalog and policies that prioritize the inclusion of innovative drugs in medical insurance have further accelerated their market penetration. For example, medical insurance expenditures on innovative drugs reached RMB 90 billion in 2023 - a 14-fold increase from 2019.
Explosive surge in clinical demand
The demand for innovative drugs in China continues to grow. With the aging population and shifting disease patterns, the need for innovative drugs is rising, particularly in fields such as tumor, cardiovascular diseases, and neurological disorders. With over 400 million patients suffering from complex conditions such as tumor and autoimmune diseases, the demand for targeted drugs like PD-1 and CAR-T treatments has increased dramatically.
Increased R&D investment
The increase in enterprise R&D investment has promoted the R&D and marketing of more innovative drugs. For instance, by rapidly targeting internationally recognized hotspots such as VEGF and EGFR, companies like Fosun Kite and Innovent have expedited their product launches. However, China's innovative drug market is still in its early stages compared to developed countries. In the United States, innovative drugs make up 80%, whereas in China, the figure is only around 10%. However, this gap is closing rapidly, and it is anticipated that by 2025, China will likely become the world's second-largest market for innovative drugs.
Advanced R&D capabilities: Three Key Stages of China's Innovative Drug R&D
Technological advancement is the core driving force behind the rise of China's innovative drug market. In recent years, China has achieved remarkable breakthroughs in the R&D of innovative drugs, particularly in cutting-edge fields such as bispecific antib...
(All Rights Reserved)